Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-2-17
pubmed:abstractText
This 12th biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials in the field of hemato-oncology, covering the publication period from September 1, 2009, through June 30, 2010. Implication for clinical practice and methodological aspects are the main principles used to select trials for this report. Studies on tyrosine kinase inhibitors for patients with chronic myeloid leukemia were identified through electronic search of MEDLINE with a broad search filter that covered all topics in hemato-oncology combined with a highly sensitive search filter for randomized studies as described in the Cochrane Handbook for Systematic Reviews of Interventions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/4-methyl-N-(3-(4-methylimidazol-1-yl..., http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones, http://linkedlifedata.com/resource/pubmed/chemical/Aminoglycosides, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal..., http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates, http://linkedlifedata.com/resource/pubmed/chemical/Erythropoietin, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles, http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine, http://linkedlifedata.com/resource/pubmed/chemical/dasatinib, http://linkedlifedata.com/resource/pubmed/chemical/epoetin alfa, http://linkedlifedata.com/resource/pubmed/chemical/fludarabine, http://linkedlifedata.com/resource/pubmed/chemical/gemtuzumab, http://linkedlifedata.com/resource/pubmed/chemical/imatinib, http://linkedlifedata.com/resource/pubmed/chemical/rituximab
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1460-2105
pubmed:author
pubmed:issnType
Electronic
pubmed:day
16
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
E1
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:21252264-Adrenal Cortex Hormones, pubmed-meshheading:21252264-Aminoglycosides, pubmed-meshheading:21252264-Antibodies, Monoclonal, pubmed-meshheading:21252264-Antibodies, Monoclonal, Humanized, pubmed-meshheading:21252264-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:21252264-Antineoplastic Agents, pubmed-meshheading:21252264-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21252264-Cyclophosphamide, pubmed-meshheading:21252264-Diphosphonates, pubmed-meshheading:21252264-Disease-Free Survival, pubmed-meshheading:21252264-Erythropoietin, pubmed-meshheading:21252264-Evidence-Based Medicine, pubmed-meshheading:21252264-Graft vs Host Disease, pubmed-meshheading:21252264-Hematologic Neoplasms, pubmed-meshheading:21252264-Hodgkin Disease, pubmed-meshheading:21252264-Humans, pubmed-meshheading:21252264-Interferon-alpha, pubmed-meshheading:21252264-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:21252264-Methotrexate, pubmed-meshheading:21252264-Piperazines, pubmed-meshheading:21252264-Protein Kinase Inhibitors, pubmed-meshheading:21252264-Protein-Tyrosine Kinases, pubmed-meshheading:21252264-Pyrimidines, pubmed-meshheading:21252264-Randomized Controlled Trials as Topic, pubmed-meshheading:21252264-Recombinant Proteins, pubmed-meshheading:21252264-Stem Cell Transplantation, pubmed-meshheading:21252264-Thiazoles, pubmed-meshheading:21252264-Treatment Outcome, pubmed-meshheading:21252264-Vidarabine
pubmed:year
2011
pubmed:articleTitle
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
pubmed:affiliation
Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. nicole.skoetz@uk-koeln.de
pubmed:publicationType
Journal Article